Tesaro, Inc.
(NASDAQ : TSRO)

( )
TSRO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 0.48%53.970.9%$1408.01m
JNJJohnson & Johnson -0.05%179.540.7%$1296.44m
BMYBristol-Myers Squibb Co. 0.45%77.591.0%$1212.16m
MRKMerck & Co., Inc. -1.53%92.320.7%$1167.02m
ABBVAbbVie, Inc. -0.92%150.561.9%$1100.30m
LLYEli Lilly & Co. 2.11%313.481.1%$967.28m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.29%142.980.0%$491.89m
AZNAstraZeneca Plc -0.17%66.701.0%$491.50m
NVSNovartis AG 0.01%91.260.2%$259.85m
GSKGlaxoSmithKline Plc -1.23%44.420.2%$257.59m
VERUVeru, Inc. 2.18%12.640.0%$253.71m
HZNPHorizon Therapeutics Plc 2.45%90.595.4%$196.03m
SGENSeagen Inc. 1.46%138.465.7%$185.67m
NVONovo Nordisk A/S 1.30%106.620.1%$182.89m
VTRSViatris, Inc. 1.44%12.010.0%$165.27m

Company Profile

Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.